Abstract：
OBJECTIVE: The objective of this registry study is to assess the utilization of pharmacogenomic (PGx) drugs among patients with chronic kidney disease (CKD).
METHODS: This study was a retrospective study of patients affiliated with the Department of Nephrology, Aalborg University Hospital, Denmark in 2021. Patients diagnosed with CKD were divided into CKD without dialysis and CKD with dialysis. PGx prescription drugs were retrieved from the Patient Administration System. Actionable dosing guidelines (AG) for specific drug-gene pairs for CYP2D6, CYP2C9, CYP2C19 and SLCO1B1 were retrieved from the PharmGKB homepage.
RESULTS: Out of 1241 individuals, 25.5% were on dialysis. The median number of medications for each patient was 9 within the non-dialysis group and 16 within the dialysis group. Thirty-one distinct PGx drugs were prescribed. Altogether, 76.0% (943 individuals) were prescribed at least one PGx drug and the prevalence of prescriptions of PGx drugs was higher in the dialysis group compared to the non-dialysis group. The most frequently prescribed drugs with AG were metoprolol, pantoprazole, atorvastatin, simvastatin and warfarin.
CONCLUSIONS: This study demonstrated that a substantial proportion of patients with CKD are exposed to drugs or drug combinations for which there exists AG related to PGx of CYP2D6, CYP2C19, CYP2C9 and SLCO1B1.
METHODS: This study was a retrospective study of patients affiliated with the Department of Nephrology, Aalborg University Hospital, Denmark in 2021. Patients diagnosed with CKD were divided into CKD without dialysis and CKD with dialysis. PGx prescription drugs were retrieved from the Patient Administration System. Actionable dosing guidelines (AG) for specific drug-gene pairs for CYP2D6, CYP2C9, CYP2C19 and SLCO1B1 were retrieved from the PharmGKB homepage.
RESULTS: Out of 1241 individuals, 25.5% were on dialysis. The median number of medications for each patient was 9 within the non-dialysis group and 16 within the dialysis group. Thirty-one distinct PGx drugs were prescribed. Altogether, 76.0% (943 individuals) were prescribed at least one PGx drug and the prevalence of prescriptions of PGx drugs was higher in the dialysis group compared to the non-dialysis group. The most frequently prescribed drugs with AG were metoprolol, pantoprazole, atorvastatin, simvastatin and warfarin.
CONCLUSIONS: This study demonstrated that a substantial proportion of patients with CKD are exposed to drugs or drug combinations for which there exists AG related to PGx of CYP2D6, CYP2C19, CYP2C9 and SLCO1B1.
摘要：
目的：本注册研究的目的是评估慢性肾脏病（CKD）患者中药物基因组（PGx）药物的使用情况。
方法：本研究是对肾内科患者的回顾性研究，奥尔堡大学医院,2021年的丹麦。诊断为CKD的患者分为未透析的CKD和透析的CKD。从患者管理系统检索PGx处方药。从PharmGKB主页检索CYP2D6，CYP2C9，CYP2C19和SLCO1B1的特定药物基因对的可操作给药指南（AG）。
结果：在1241个人中，25.5%进行透析。非透析组患者的中位用药数量为9，透析组为16。处方了31种不同的PGx药物。总之,76.0％（943人）至少服用了一种PGx药物，透析组PGx药物处方的患病率高于非透析组。最常用的AG处方药是美托洛尔，泮托拉唑,阿托伐他汀,辛伐他汀和华法林.
结论：这项研究表明，相当比例的CKD患者暴露于存在与CYP2D6、CYP2C19、CYP2C9和SLCO1B1的PGx相关的AG的药物或药物组合。
方法：本研究是对肾内科患者的回顾性研究，奥尔堡大学医院,2021年的丹麦。诊断为CKD的患者分为未透析的CKD和透析的CKD。从患者管理系统检索PGx处方药。从PharmGKB主页检索CYP2D6，CYP2C9，CYP2C19和SLCO1B1的特定药物基因对的可操作给药指南（AG）。
结果：在1241个人中，25.5%进行透析。非透析组患者的中位用药数量为9，透析组为16。处方了31种不同的PGx药物。总之,76.0％（943人）至少服用了一种PGx药物，透析组PGx药物处方的患病率高于非透析组。最常用的AG处方药是美托洛尔，泮托拉唑,阿托伐他汀,辛伐他汀和华法林.
结论：这项研究表明，相当比例的CKD患者暴露于存在与CYP2D6、CYP2C19、CYP2C9和SLCO1B1的PGx相关的AG的药物或药物组合。
